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Abstract 
PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute 
lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities 
of the class I PI3K isoforms p110γ and p110δ play a major role in the development and 
progression of PTEN null T-ALL, it has yet to be determined whether their contribution to 
leukemogenic programing is unique from that associated with NOTCH1 activation. Using 
a Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 
pathways are aberrantly upregulated, we now demonstrate that the combined activities of 
PI3Kδ/γ have both overlapping and distinct roles from NOTCH1 in generating T-ALL 
disease signature and in promoting tumor cell growth. Treatment of diseased animals with 
either a dual PI3Kδ/γ or a γ-secretase inhibitor (GSI) reduced tumor burden, prolonged 
survival, and induced proapoptotic pathways. Consistent with their similar biological 
effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in 
gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL 
cell lines conferred resistance to both inhibitors, suggesting a point of pathway 
convergence. Of note, interrogation of transcriptional regulators and analysis of 
mitochondrial function showed that PI3Kδ/γactivity played a greater role in supporting 
the disease signature and critical bioenergetic pathways. Results provide insight into the 
interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual 
PI3Kδ/γ inhibition in the context of NOTCH1 and cMYC signaling.
3 
Introduction 
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease characterized by
frequent relapse, resistance to chemotherapy, and reduced survival as compared to B-
precursor ALL (1). Consistent with most lymphoid malignancies, tumor development and 
disease progression depend upon deregulation of an oncogene(s) and/or tumor suppressor 
genes that permit unchecked proliferation and resistance to programmed cell death. 
Chromosomal translocations driven by T-cell receptor-regulatory elements occur 
frequently in T-ALL, resulting in aberrant expression of a select group of transcription 
factor oncogenes such as TAL1, LMO1, LMO2, TLX1, and TLX3 (2-4). These gene 
rearrangement events are typically accompanied by constitutive NOTCH1 signaling due 
to mutations within its heterodimerization (HD) and C-terminal proline-, glutamic acid-, 
serine-, and threonine-rich (PEST) domains, causing ligand-independent activation and 
increased stability of the γ-secretase cleaved intracellular domain (ICN1) (5, 6).
Subsequent nuclear translocation of ICN1 stimulates transcription of downstream target 
genes such as HES1, DTX1, and MYC, the latter being an essential mediator of NOTCH1 
signaling (7, 8). cMYC is a known master transcription factor that regulates genes 
essential for cell metabolism, proliferation and survival (9, 10). 
Aberrant activation of the PI3K/AKT pathway has also been implicated in the 
oncogenic transformation and tumor progression of T-ALL, and is associated with 
aggressive biological features, drug resistance and poor prognosis (11-13). In the 
majority of cases this results from a loss or reduced function of the phosphatase and 
tensin homolog (PTEN) tumor suppressor, which limits levels of PIP3 generated by class I 
PI3Ks (14). Interestingly, NOTCH1 has also been reported to indirectly regulate this 
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signaling pathway due to its ability to alter PTEN expression, which has been implicated 
in inducing GSI resistance in T-ALL by switching “oncogene addiction” (15). However, 
other studies have shown that PTEN status does not always correlate with GSI 
responsiveness, and that NOTCH1 and PI3K/AKT pathways may work in concert to 
promote tumor growth and survival (16, 17).  
Previously, we have demonstrated the importance of the class I PI3K isoforms p110
γ and p110δ in T cell development and their ability to cooperate as non-classical
oncogenes in supporting leukemogenesis in the absence of negative regulation by PTEN 
(18, 19). This was further evidenced by our observations that a highly selective dual 
PI3Kγ/δ inhibitor CAL-130 significantly reduced disease burden, prolonged survival of 
mice with established PTEN null T-ALL, and induced apoptosis in human T-ALL tumor 
cells with aberrant PI3K/AKT signaling. Yet, it remains to be determined whether PI3Kγ/
δ regulate transcriptional pathways typically associated with activated NOTCH1 (e.g. 
cMYC). Investigations along these lines are essential for establishing whether p110-
selective small molecule inhibitors could synergize or substitute for GSIs in the treatment 
of T-ALL. Indeed, the variable antitumor effects of GSIs reported in phase I clinical trails 
would suggest that such an approach is warranted (20, 21). To this end, we evaluated the 
molecular and genetic interplay between these pathways using the Lmo2-driven mouse 
model of T-ALL where both PI3K/AKT and NOTCH1 are activated (22-23). 
Additionally, gene set enrichment and pathway analyses were used to determine if these 
disparate pro-oncogenic pathways controlled similar genes and transcriptional regulators 
that are determinants of the disease signature associated with T-ALL.  
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Materials and Methods 
Mice  
Cohorts of CD2-Lmo2 and Gt(ROSA)26Sortm13(CAG-MYC, -CD2*)Rsky/J;Lck-cre/Ptenfl/fl, both 
on C57BL/6J background, were monitored for the onset of leukemia (19, 22, 25). 
Experiments were performed in accordance with guidelines set forth by the Institutional 
Animal Care and Use Committee of Columbia University. Animals with established T-
ALL received either the dual PI3Kδ/γ inhibitor CAL-130 (10 mg/kg every 8 hours; 
Calistoga Pharmaceuticals) (19) or the γ-secretase inhibitor dibenzazepine (DBZ; 10 
µmol/kg IP daily; Tocris) (26) for a total of 7 days (27). Kaplan-Meier survival and 
statistical analyses were performed using GraphPad Prism Version 6.0 software. Values 
were considered significant at P < 0.05. 
Primary leukemia samples and cell lines 
Cryopreserved human T-ALL samples were provided by St. Jude Children's Research 
Hospital and Vanderbilt University Medical Center after appropriate IRB review. All 
samples were collected with informed consent. Murine CD2-Lmo2 T-ALL cell lines 
03007 and 03027 were generated as previously described (23). In brief, they were 
generated in the Davé lab (Vanderbilt University) from T-cell leukemia that arose in 
transgenic B6.CD2-Lmo2 mice. Once established in culture, aliquots of cells were banked 
in liquid nitrogen and samples obtained for this study in 2014. The cell lines were 
identified and then confirmed immediately before use by their immunophenotpye and by 
T-cell receptor Jβ rearrangement (23).
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Retroviral transduction of murine cell line 
Plasmid pMSCV-IRES-mCherry and pMSCV-cMyc-IRES-mCherry were kindly 
provided by the laboratory of Dr. Riccardo Dalla-Favera (Columbia University, NY, 
NY). Retroviruses were produced in ecotropic packaging cell line 293T Platinum-E 
according to manufacturer’s instructions (Cell Biolabs Inc). Viral transduction was 
performed using the RetroNectin® (Takara) and spinoculation method as previously 
described (28).  
Mutation detection 
Sequencing of the Notch1 and Pten genes was performed on primary mouse T-ALL cells 
by PCR using Pfu DNA polymerase (Stratagene) with primers specific for exon 34, and 
exons 3 through 7, respectively.  
FACS  
Preparation, staining, and detection of cell surface and cytoplasmic proteins in primary T-
ALL cells and murine T-ALL cell lines were performed as previously described (19).  
Western blot analysis 
Cell lysates were prepared on ice in M-PER Mammalian Protein Extraction reagent 
(Pierce) containing a cocktail of protease and phosphatase inhibitors (19). Lysates were 
subjected to SDS-PAGE, transferred to PVDF membrane (Immobilon-P, Millipore), and 
membranes probed by overnight incubation (4°C) with appropriate primary antibodies. 
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Bound antibodies were visualized with HRP-conjugated secondary antibodies and ECL 
chemistry (SuperPico West, Pierce). 
Drug synergy and cell viability studies 
Murine CD2-Lmo2 T-ALL cell lines 03007 and 03027 were plated at optimal density into 
384-well tissue culture plates (Greiner 781080) employing the Cell::Explorer automation
system (PerkinElmer). CAL-130 or the GSI CompE (ENZO Biochem) (29) (was added 
using HP D300 Digital Dispenser, and drug activity measured at 60 hours using Cell 
Titer Glo (Promega). The standard reference model of Bliss independence was employed 
for the results analysis (30). 
Cell lines were also grown in 6 well plates and individually treated with DMSO, 
CAL-130, IC87114 (Calistoga) (31) CompE for 72 hours. Proliferation and cell death 
were determined by cell counting with trypan blue and by staining with PI (BD 
Biosciences) followed by flow cytometric analysis, respectively. For primary murine and 
human T-ALL samples, cells were harvested from thymi of diseased animals and plated 
with MS5-DL1 stromal cells in the presence of recombinant IL-7 and FLT-3 (mouse) or 
recombinant IL-7, FLT-3 and SCF (human). T-ALL cell viability following 72 hours of 
drug treatment was assessed using the BD Cell Viability kit (BD Biosciences) coupled 
with fluorescent counting beads as previously described (19). After 72 hours of treatment, 
absolute number of cells in DMSO control was set to 100%. 
Mitochondria isolation and respiration studies 
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Mitochondria were isolated from murine T-ALL cells treated with DMSO or CAL-130 
(2.5 µM, 12 h) and respiration analyzed in TRIS-MOPS buffer using Clark’s type 
electrode (Hansatech, UK) as described (32). 
OCR measurements 
Murine CD2-Lmo2 T-ALL cell lines treated with CAL-130 (2.5µM, 12 h), CompE (1µM, 
48 h) or vehicle (DMSO) were centrifuged and directly suspended in XF assay medium 
(Seahorse Biosciences) supplemented with 10 mM glucose (Sigma-Aldrich) and 10 mM 
sodium pyruvate (Invitrogen). For primary CD2-Lmo2 T-ALL tumors, cells were grown 
on MS5-DL1 stromal cells in the presence of recombinant IL-7 and FLT-3 (mouse) for 
24 h before the addition of DMSO, CAL-130 (2.5 µM, 12 h) or CompE (1µM, 48 h). 
Tumor cells were then disrupted by pipetting, filtered through a 40 µm strainer to 
separate from the stromal cells, and centrifuged and suspended in XF assay medium 
(Seahorse Biosciences) supplemented with 10 mM glucose (Sigma-Aldrich) and 10 mM 
sodium pyruvate (Invitrogen). Primary tumors or tumor cell lines were added to a XF24 
cell culture microplate coated with poly-L-Lysine (Sigma-Aldrich). After 30 minutes at 
37°C, OCR was measured using a XFe24 Analyzer (Seahorse Biosciences) after serial 
injections of oligomycin (1µM), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 
(FCCP) (0.75 µM), rotenone (1 µM) and antimycin A (1µM). Coupling efficiency, as a 
measure of the fraction of basal mitochondrial OCR used for ATP synthesis, was 
assessed by the decrease in respiration on inhibiting ATP synthase with oligomycin. Cell 
respiratory control ratio is the ratio of the uncoupled OCR (rate after FCCP injection) to 
OCR in the presence of oligomycin. Spare respiratory capacity was measured by the ratio 
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of the uncoupled OCR to the basal rate. Experiments were performed using at least 3 
biological replicates and all values were internally normalized (33).  
Glucose Uptake Assessment 
Murine CD2-Lmo2 T-ALL cell lines cells treated as described were resuspended in 
glucose-free RPMI-1640 medium containing 1% fetal calf serum (FCS) and 150 µM 2-
NBDG (Life Technologies), incubated for 10 min at 37° C, washed with ice-cold PBS 
and analyzed using flow cytometry. Apigenin (100µM, 30 min treatment), an inhibitor of 
Glut1 expression, was used as a positive control. 
Microarray procedure 
A representative murine CD2-Lmo2 derived T-ALL cell line (03007) was treated with 
DMSO (0.6%) or CAL-130 (2.5 µM; 10 h) or CompE (1 µM; 48 h).  Biological 
triplicates were performed with each experimental condition and gene expression 
profiling performed by Expression Analysis, Inc. using the Affymetrix Mouse Genome 
430 array (#901570). Microarray data were then normalized using the Robust MultiChip 
Averaging (RMA) algorithm as implemented in the Bioconductor package Affy (34). A 
modified t-test was used in Bioconductor Limma package to identify differentially 
expressed probe sets between each drug treatment group and control group (35). The P-
values from Limma analysis were adjusted by Benjamini and Hochberg method to control 
false discovery rate (FDR) and genes were ranked to identify top 50 up and 50 down 
regulated genes for each treatment condition (36).  
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Statistical analyses 
Results are expressed as mean ± SEM for a minimum of 3 independent experiments.  
Statistical analysis was performed using either the Student unpaired t-test or two-way 
ANOVA followed by Bonferroni post-test.  P values < 0.05 were considered significant. 
Further detailed statistical analysis of the microarray data and information on 
experimental methods can be found in supplemental materials available on the Molecular 
Cancer Therapeutics Web site. 
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Results  
Lmo2-driven T-ALL is defined by constitutive activation of PI3K/AKT and 
NOTCH1 pathways   
Disease penetrance was 100% with a median survival rate of 227 days in CD2-Lmo2 
transgenic mice (Fig. 1A). Tumor cells displayed high levels of both phosphorylated 
AKT (Thr308 and Ser473) and intracellular NOTCH1 (ICN) with activation of 
downstream targets (Fig. 1B); all tumors expressed the p110γ and p110δ catalytic 
domains of class I PI3Ks (Fig. 1 C). Of note, the majority of Lmo2-driven T-ALL lacked 
expression of PTEN, acquired Notch1 mutations within the PEST domain 
(Supplementary Table S1) and had evidence of upregulation of the Notch1 target genes 
such as Deltex1 (~4-fold; Fig. 1D). Moreover, the majority of circulating blasts had an 
immunophenotype characteristic of NOTCH1-induced T-ALL in mice: CD8 single 
positive or CD4/CD8 double positive with high expression of CD25 (Fig. 2A and B). 
Thus, the CD2-Lmo2 transgenic animal model of T-ALL provided an ideal system to 
determine whether the combined activities of PI3Kδ/γ regulate similar or distinct 
oncogenic programs typically associated with NOTCH1 activation.  
PI3Kδ/γ blockade or GSI reduces leukemia burden and prolongs survival 
To determine the reliance of Lmo2-driven T-ALL on the PI3K/AKT versus NOTCH1 
pathway, we treated diseased animals with either the dual PI3Kδ/γ inhibitor CAL-130 (10 
mg/kg every 8 hours) or the potent γ-secretase inhibitor DBZ (10 µmol/kg per day) for 7 
days. Previously we have shown that CAL-130 is highly selective for the p110γ and 
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p110δ catalytic domains of class I PI3Ks by virtue of its ability to (1) yield an 
immunologic phenotype similar to that of mice lacking both p110 isoforms when 
administered to WT animals, and  (2) significantly reduces tumor burden and prolong 
survival in mice that develop PTEN null T-ALL (19). Despite NOTCH1 activation, all 
mice had a rapid response to the dual PI3Kδ/γ inhibitor as evidenced by a reduction in 
circulating blasts and presence of apoptotic cells 4 days post treatment (detected sub-G0 
population after propidium iodide (PI) staining) (Fig. 2A). Administration of DBZ also 
reduced disease burden (Fig. 2B) and resulted in a similar prolongation in survival: 
median of 27 days for DBZ-treated versus 29 days for CAL-130 treated animals (Fig. 2C, 
P = 0.64).  
In order to investigate the direct effects of PI3K/AKT and NOTCH1 inhibition on 
tumor cell proliferation and survival, we performed in vitro co-culture of primary 
leukemic blasts from mice and human T-ALLs using MS5-DL1 stromal cells (19). 
Consistent with in vivo results, primary T-ALL cell viability was significantly reduced in 
the presence of either CAL-130 or the γ-secretase inhibitor CompE (Fig. 3A, 
Supplementary Fig. S1A and 1B, and Supplementary Table S1) while the viability of 
stromal cells was not affected by either compound. 
We next evaluated the effects of these inhibitors alone or in combination using 
two representative T-ALL cell lines, designated 03007 and 03027, which were derived 
from diseased CD2-Lmo2 transgenic animals (23). Consistent with results obtained with 
primary tumors, treatment of either cell line with CAL-130, but not the p110δ selective 
inhibitor IC87114, had a cytostatic effect and induced cell death within 24 hours based on 
PI staining (Fig. 3B and Supplementary Fig. S1C). The effects of CompE were similar 
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albeit delayed (Fig. 3C and Supplementary Fig. S1D). To determine whether the 
combination of CAL-130 and CompE would be synergistic in nature, we used a high-
throughput cell viability screen based on cellular ATP detection and the Bliss 
independence model to quantify the degree of synergy between the pathways (30). 
Excess over Bliss (EoB) was calculated as the difference between the observed effect and 
the predicted response; a 5-10% EoB response was considered as weak, 10-20% as 
moderate, and over 20% was considered as strong synergism. Results indicate that 
CAL-130 (2.5 µM) in combination with CompE did not yield a synergistic effect in either 
cell line, suggesting redundancy in the NOTCH1 and PI3K/AKT pathways in Lmo2-
driven T-ALL (Supplementary Fig. S2).  
PI3Kδ/γ regulate cMYC expression independently of NOTCH1 
NOTCH1 directly regulates cMYC expression, which governs an oncogenic program 
supporting T-ALL cell growth and survival (7,8). Accordingly, CompE blocked 
NOTCH1 activation in Lmo2-driven T-ALL cell lines and also reduce protein levels of 
cMYC, albeit at distinct time points (24 hours and 48 hours, respectively) (Fig. 3D and 
Supplementary Fig. S1E). In contrast to the delayed effects associated with GSI, dual 
inhibition of PI3Kδ/γ activity abolished cMYC protein but not transcript expression 
within 12 hours of treatment (Fig. 3D and 3E). Importantly, CAL-130 was still able to 
inhibit activation of AKT (phosphorylation of Thr308 and Ser473) and its downstream 
targets such as glycogen synthase kinase-3β (GSK3β), the eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1), and the ribosomal protein p70 S6 kinase 
(p70 S6K) (19), which play a major role in cell cycle progression and tumor cell 
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proliferation (Fig. 3F and Supplementary Fig. S1F). Of note, blockade of 
PI3Kδ/γactivity or GSI abrogated the expression of the anti-apoptotic effectors MCL-1 
and phospho-BAD (S136) and lead to upregulation of pro-apoptotic BIM (Supplementary 
Fig. S3A and S3B), with > 50% of CAL-130 treated cells becoming apoptotic by 24 
hours in contrast to those treated with CompE as determined by flow cytometry (sub-G1) 
(Supplementary Figs. S3C-F). In contrast, the majority of effects of CompE were not 
observed until 48 hours.  
In order to confirm that loss of cMYC protein expression is essential for CAL-130 
or CompE-induced tumor cell death, we generated an Lmo2-driven murine T-ALL line 
with constitutive cMYC expression. Indeed, over expression of this oncogene permitted 
continued tumor cell growth despite incubation with either inhibitor. Moreover, cMYC 
protein levels remained constant in contrast to cells expressing vector alone (Fig. 4A-F). 
To further demonstrate that down regulation of cMYC is essential for the anti-
tumorigenic effects CAL-130 and that it may exert this effect independent of NOTCH1 
activation, we crossed Gt(ROSA)26Sortm13(CAG-MYC, -CD2*)Rsky/J mice that overexpress cMyc 
with Lck-cre/Pten(fl/fl) mice that lack Pten. Previously we have shown that T-ALL that 
develops in PTEN-null mice is exquisitely sensitive to the dual PI3Kγ/δ inhibition (19). 
In contrast, T-ALL with enforced cMYC expression was resistant to CAL-130 treatment 
(10 mg/kg every 8 hours for 7 days) and showed continued expansion of circulating blasts 
(Ki67+/Thy1.2+ population) and lack of PI-staining (Fig. 4G).  
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PI3Kδ/γ and NOTCH1 have overlapping gene regulatory networks in Lmo2-driven 
T-ALL
To better understand the genetic basis by which PI3Kδ/γ and NOTCH1 regulate tumor 
progression in Lmo2-driven T-ALL, we generated gene expression signatures based on 
disease phenotype and drug treatment. Global gene expression profiles were obtained in 
triplicate from tumor cells cultured in the presence of CAL-130 (2.5 µM), CompE (1 µM), 
or DMSO. Drug treated cells were harvested at time points known to affect cMYC 
expression (12 hours and 48 hours, respectively). A Venn diagram was created to 
illustrate the overlap in genes altered by either PI3Kδ/γ blockade (red circle) or GSI 
(green circle) using a false discovery rate (FDR) of 0.0005 as cut off (Fig. 5A). Of note, 
ten-fold more genes were affected following PI3Kδ/γ blockade and included the majority 
(~62%) of genes altered by GSI monotherapy, a highly significant finding (Fisher's exact 
test, P < 2.2×10-16). Heat maps were also generated from complete linkage hierarchical 
cluster analyses of statistically significant changes in gene expression associated with 
drug treatment versus vehicle control (Fig. 5B). In the case of PI3Kδ/γ blockade, down-
regulated genes also included those involved in cMYC-regulated cellular metabolism 
and/or metabolic reprogramming such as the glycine/serine biosynthetic pathway (e.g. 
Phgdh, FDR = 6×10-8; Shmt1, FDR = 8.2×10-8; Shmt2, FDR = 6.2×10-8, folate 
metabolism (e.g. Mthfd1, FDR = 6.04×10-8), glycolysis (e.g. Hk-2, FDR = 5.4×10-8), 
nucleotide metabolism (Ak4, FDR = 2.3×10-8) and mitochondrial proline metabolism and 
synthesis (Pycr1, FDR = 3.1×10-7) (37-41). As expected, gene expression profiling of 
CompE-treated cells demonstrated significant downregulation of canonical NOTCH1 
target genes including Hes1 (FDR = 1.1×10-7), Hey1 (FDR = 2.6×10-8), and Deltex1 
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(FDR = 4.4×10-6), as well as modulating the expression of genes involved in glycolysis 
(e.g. Slc2a3, FDR = 4.14×10-6; Hk2, FDR = 1.68×10-5) and nucleotide metabolism (e.g. 
Ak4, FDR=1.66×10-3)  (42). 
We next defined a murine T-ALL disease signature by ranking all genes based on 
their differential expression in T-ALL samples compared to wild type murine thymocytes. 
To determine the contribution of PI3Kδ/γ and NOTCH1 to the overall disease signature, 
we performed a gene set enrichment analysis (GSEA) of the 200 most transcriptionally 
activated and repressed genes following treatment with either CAL-130 or CompE in 
differentially expressed genes. Although both drugs significantly inverted the T-ALL 
disease signature, underscoring the importance of these signaling pathways in 
maintaining the leukemic phenotype (Fig. 5C), the enrichment was much more 
significant with CAL-130 (normalized enrichment score (NES) of -5.8 (P < 0.0001) for 
CAL-130 versus NES of -2.6 (P = 0.006) for CompE. To show that treatment of murine 
cells is highly consistent with treatment of human cells, we assessed whether the top 200 
most differentially expressed genes following CompE treatment of murine T-ALL cells 
were significantly enriched in human-to-mouse mapped genes differentially expressed 
following CompE treatment of human cells (Fig. 5D). To accomplish this goal, we 
integrated data from seven distinct dataset representing human T-ALL cells treatment 
with CompE (7). Analysis confirms that results from drug treatment of Lmo2-driven 
murine T-ALL are relevant to human T-ALL.  
Previously, we have shown the existence of Master Regulator (MR) proteins 
responsible for causally (i.e., physically) regulating the transcriptional state of a cancer 
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cell (43). As such, their activated and repressed targets are highly enriched in genes that 
are over- and under-expressed in tumor cells, respectively, and can thus be efficiently 
identified by analyzing a regulatory network that represents the transcriptional targets of 
every protein using the VIPER (Virtual Proteomics by Enriched Regulon) algorithm (44). 
VIPER is an extension of the Master Regulator Inference algorithm (MARINa) (45), 
which supports analysis of MR proteins on an individual sample basis. Such an analysis 
has helped elucidate novel mechanisms of tumorigenesis, progression, and drug 
sensitivity in glioma, leukemia, lymphoma, prostate and breast cancer, among others. As 
MR protein activity efficiently recapitulates overall tumor state and drug response, we 
first identified key T-ALL-specific MR proteins and then assessed whether compound 
treatment could effectively reverse their activity.  MR proteins were inferred by VIPER 
analysis of a previously assembled, genome-wide T-ALL-specific regulatory network 
(interactome) using a signature of a Lmo2-driven murine T-ALL cell line (7) compared to 
wild type murine thymocytes. This interactome was previously used to successfully 
elucidate the Mechanism of Action (MoA) of small molecule compounds targeting 
human T-ALL pathways (7). The ViPER algorithm was then used to compute the activity 
of each of the top 40 T-ALL MR proteins following drug perturbation. This was 
accomplished by computing the enrichment of their regulons (i.e., the set of their 
transcriptional targets), as represented in the interactome, in genes differentially 
expressed following drug treatment (drug signature). Although the gene signatures for the 
two drugs overlapped significantly (P < 6 x 10-13, Fisher exact test), ~3-fold more T-ALL 
MRs were reverted by CAL-130 compared to GSI CompE (Fig. 5E and Supplementary 
Table S2; NES < -1.96 and P < 0.05). Of note, Lyl1, Tal1 and Hhex were not affected by 
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CAL-130 according to our analysis. We also performed GSEA of ~4,500 annotated gene 
sets collected from Molecular Signatures Database (MSigDB) on the CAL-130 and 
CompE induced gene signatures to study the perturbed pathways (46). Although CAL-
130 altered many of the same genes as compared to CompE, it had stronger effects on 
pathways regulated by PML (originally identified as a tumor suppressor in acute 
promyelocytic leukaemia) (NES 2.57 and P < 0.01 vs. NES 0.82 and P = 0.41), EDF1 
(NES -3.58 and P < 0.005 vs. NES -0.53 and P = 0.6) and IRF9 (NES 3.18 and P < 0.005 
vs. NES 0.07 and P = 0.944). Thus, CAL-130 treatment recapitulated majority of 
mechanism of action of CompE, while reversing the activity of a large number of 
additional master regulators and pathways associated with the T-ALL tumor cell state.  
To access drug effects on cMYC activity, we analyzed published microarrays of 
human T-ALL (47) and used GSEA to compute the enrichment of cMYC-regulated genes 
differentially expressed following CAL-130 or CompE treatment (Fig. 5F and 
Supplementary Table S3). Although genes regulated by cMYC were observed in both 
drug treatment signatures (P < 10-3), CAL-130 treatment had a greater effect in terms of 
reversing the global expression of cMYC targets (NES of -6.23), compared to CompE 
(NES of -5.10). Of note, ~74% of genes regulated by cMYC were in the top 1,000 genes 
in the CAL-130 treated gene expression signature as compared to ~42% in the CompE 
treated gene signature (Supplementary Table S3).  
PI3Kγ/δ and NOTCH1 differentially modulate metabolic and mitochondrial 
pathways in leukemic cells  
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To better assess the functional categories represented by the set of genes altered in 
response to the inhibitors, we performed pathway analysis using DAVID (48). A highly 
conservative threshold (P < 1x10-5) was used to identify the top down-regulated genes in 
CAL-130 or CompE treated Lmo2-driven T-ALL cells. In the case of PI3Kδ/γ blockade, 
there was a significant enrichment in functional categories related to cellular metabolism 
and most interestingly, pathways that regulate mitochondrial activity (Fig. 6A and 6B). 
CompE treatment not only altered similar metabolic pathways including those related to 
carbohydrate, nucleotide, pyruvate and TCA (Fig. 6C and Supplementary Fig. S4A and 
S4B), but also reduce glucose uptake in T-ALL tumor cells as observed for CAL-130 
(Fig. 6D and Supplementary Fig. S5A); it did not, however, appear to affect genes that 
directly regulate mitochondrial function (7, 42, 49).  
As aforementioned, blockade of PI3Kγ/δ activity preferentially altered genes that 
affect mitochondrial activity, such as those involved in the electron transport chain and 
oxidative phosphorylation (Fig. 7A and Supplementary Fig. S4C). Consistent with this 
observation, CAL-130 but not CompE significantly reduced in situ oxygen consumption 
rates (OCRs), ATP levels and spare respiratory capacity, the latter indicating that PI3Kγ/δ 
inhibition limits the ability of tumor cell lines and primary tumor cells to respond to stress 
or metabolic challenge (Fig. 7B-E and Supplementary Fig. S5B-H). Further evidence to 
support these observations was provided by directly studying mitochondria isolated from 
CAL-130 treated tumor cells. Indeed, a robust inhibition of resting and phosphorylating 
respirations rates in purified mitochondria were observed suggesting that the alterations in 
genes encoding the respiratory chain complexes I (e.g. Ndufa12), II (e.g. Sdhb), and III 
(e.g. Cyc1) were functionally significant (Fig. 6B and 
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7F). Our experiments also suggested dysregulation of complex IV as evidenced by the 
marked depression of mitochondrial respiration with TMPD-ascorbate as substrate (50). 
Of note, CAL-130 treatment affected the expression of mitochondrial protein serine 
hydroxymethyl transferase (SHMT2; Figure 7F, insert). SHMT2 is a key enzyme in the 
serine / glycine synthesis pathway that plays a critical role in the metabolic 
reprogramming in cancer and is a transcriptional target of cMYC (51). Thus, PI3Kγ/δ 
inhibition not only affects major metabolic pathways that support tumor homeostasis but 
also affects the bioenergetics of T-ALL cells. 
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Discussion 
Cumulative evidence indicates that the PI3K/AKT and NOTCH1 pathways not only 
contribute to the malignant transformation of T cell progenitors but also play a major role 
in regulating the growth, metabolism, and survival of T-ALL. Here, we explored the 
interdependence of these oncogenic pathways in promoting tumor cell maintenance, 
which has profound implications for the development of a rational therapeutic strategy to 
treat this aggressive hematologic malignancy. It is for this reason that we chose the 
Lmo2-driven transgenic mouse model of T-ALL that is characterized by the spontaneous 
accumulation of several oncogenic mutations in T cell precursors, resulting in the co-
activation of PI3K/AKT and NOTCH pathways. In the context of this model, we now 
provide evidence that (1) although there is no preferential addiction of tumor cells to 
either pathway, PI3Kδ/γ blockade appears to exert a more rapid and potent effect on 
tumor cells than GSI, and (2) there is a lack of synergy between PI3K/AKT and 
NOTCH1 in supporting tumor cell proliferation and survival.  
Previous studies have demonstrated that NOTCH1 can indirectly impact on the 
activity of the PI3K/AKT pathway by controlling a transcriptional network that regulates 
PTEN expression in leukemic T cells (15). Indeed, this mechanism is believed to be 
responsible for bypassing the requirement for aberrant NOTCH1 signaling that normally 
supports tumor cell growth and metabolism. In contrast, our studies indicate that 
NOTCH1 does not regulate PI3Kδ/γ activity or PTEN expression, suggesting that these 
pathways can function independently of one another. This is exemplified by the lack of 
correlation between activation status of either pathway and the ability of primary mouse 
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or human T-ALL cells to respond to treatment with CompE or CAL-130. That said, they 
do appear to control similar oncogenic networks that are indispensible for tumor cell 
maintenance.  Results indicate a genetic underpinning for these observations as evidenced 
by the considerable overlap in genes regulated by both signaling pathways, including 
cMYC. The latter was confirmed by the ability of constitutively expressed cMYC to 
reverse the effects of either inhibitor. Collectively, these data demonstrate that PI3Kδ/γ 
can support a NOTCH1-independent pathway of cMYC activation in T-ALL, which may 
account for similar reduction in cell growth and survival but lack of synergistic effect 
observed in response to CAL-130 and/or CompE (52).  
Why then does PI3Kδ/γblockade appear to exert a more rapid and potent anti-
leukemic effect than inhibition of NOTCH1 by GSI? Gene expression profiling and 
pathway analysis based on DNA microarrays of drug treated Lmo2-driven T-ALL 
provided possible answers. On a global scale, CAL-130 treatment had a greater effect on 
altering the disease signature compared to CompE, as demonstrated by the reversal of top 
master regulators (e.g. HNRNPAB, Tp53, PA2G4, ASH2L and SNAPC5) and affects on 
pathways (e.g. PML, EDF1, and IRF9) associated with the CD2-Lmo2 T-ALL tumor cell 
state. This was consistent with the ability of CAL-130 to down regulate a 10-fold greater 
number of genes at an early time point. Interestingly, the majority of altered genes are 
known to support cellular metabolism and/or the metabolic reprogramming implicated in 
tumor progression, including those involved in serine/glycine metabolism, polyamine 
synthesis, and glycolysis. Indeed, the ability of cancer cells to alter their metabolism is 
essential to support the increased energy demands associated with rapid tumor growth. 
Germane to this study is the ability of the PI3K/AKT pathway to act as a master regulator 
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of aerobic glycolysis and cellular biosynthesis that critically relies on mitochondrial 
bioenergetics (53, 54). In fact, the shift from oxidative to more glycolytic metabolism is 
one of the most common changes found in tumor cells. Although our results clearly 
demonstrated that PI3Kγ/δ blockade or GSI significantly reduce glucose uptake in leukemic cells, 
only the former was able to rapidly alter mitochondrial function. Indeed, we noted that 
genes encoding proteins involved in oxidative phosphorylation were uniquely susceptible 
to CAL-130, including those essential for the mitochondrial respiratory chain complex 
formation (FDR < 0.005). Consistent with this observation was the robust inhibition of 
mitochondrial resting and phosphorylating respirations rates. This finding is of particular 
interest as enhancement in the bioenergetics properties of tumor cells is thought to be a 
prerequisite for survival.  
Overall, our results suggest the existence of a regulatory circuit linking NOTCH1 
and PI3K/AKT signaling, with cMYC serving as a crucial node of convergence that 
intertwines but does preferentially support the activity of either pathway. Moreover, we 
provide new insights into the mechanism(s) by which the combined activities of PI3Kδ/γ 
contribute to the maintenance of T-ALL and how pharmacological blockade of these two 
isoforms exerts a more rapid and pronounced effect on tumor cell proliferation than GSI, 
yet can yield similar rates of survival of diseased animals. This involves regulating 
transcriptional pathways and genes typically associated with NOTCH1, as well as distinct 
metabolic and bioenergetic pathways essential for tumor progression and survival. These 
results provide a rationale for the combined targeting of p110γ and p110δ catalytic 
domains of class I PI3Ks in T-ALL where NOTCH and/or PI3K/AKT pathways are 
dysregulated.  
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Figure legends 
Figure 1. PI3K/AKT and NOTCH1 pathways are co-activated in Lmo2 driven T-ALL in 
mice. A, Kaplan-Meier survival curves for CD2-Lmo2 transgenic animals. Representative 
immunoblots of the primary T-ALL cells from diseased mice showing protein expression 
of PTEN and cMYC as well as AKT and NOTCH1 activation state (B), and expression of 
p110 catalytic subunits of class I PI3K (C).  D, Expression levels of Notch1 and its target 
Deltex1 in primary murine tumors compared to wild-type (WT) DN3 thymocytes as 
determined by qRT-PCR (n = 7). ***, P < 0.0001; ns = not significant.  
Figure 2. Combined PI3Kδ/γ blockade or GSI reduces tumor burden and prolongs the 
survival of mice with Lmo2-driven T-ALL. A and B, Flow cytometric analysis of disease 
status in CD2-Lmo2 transgenic mice immediately before and 4 days and 7 days after 
initiating treatment with either the dual PI3Kδ/γ inhibitor CAL-130 (A; 10 mg/kg every 
8h) or the γ-secretase inhibitor DBZ (B; 10 µmol/kg daily) for 7 days. Tumor response to 
drug treatments was confirmed by changes in circulating blasts (Thy1.2+/Ki67+) and 
evidence of propidium iodide (PI)-staining. C, Kaplan-Meier survival curves for CD2-
Lmo2 mice with T-ALL treated with either CAL-130 or DBZ for 7 days.  The latter only 
included animals that received the full course of drug, P = 0.64 (log-rank test).   
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Figure 3. PI3Kδ/γ inhibition promotes tumor cell death irrespective of NOTCH1 
activation status. A, Analyses of primary CD2-Lmo2 mouse T-ALL tumor cell viability 
in the presence of increasing concentrations of CAL-130 or CompE for 72 h. B-C, 
Proliferation and survival analysis of a representative Lmo2-driven T-ALL tumor cell line 
(03007) cultured in the presence of increasing concentrations of CAL-130 (B) or CompE 
(C) for 72 h. Data represent mean ± SEM (n = 3 in triplicate). Statistical significance was 
determined by Student’s t test for drug treated cells relative to control. *, P < 0.01; **, P < 
0.001; ***, P < 0.0001; ns (not-significant). D, Immunoblots of PTEN and cMYC 
expression as well as NOTCH1 activation state in a representative CD2-Lmo2 T-ALL 
cell line (03007) cultured in the presence of CAL-130 (6, 12, and 24 hours) or CompE 
(24 and 48 hours). E, Expression levels of cMyc in the identical tumor cell line after 12 h 
of treatment with CAL-130 (2.5 µM) as determined by qRT-PCR (n = 3). F, 
Immunoblots depicting AKT and the activation state of its downstream effectors in the 
same cell line at the indicated duration of treatments.  
Figure 4. Overexpression of cMYC results in resistance to CAL-130 and GSI treatments. 
A-D, FACS dot plots (A and B) and viability bar graphs (C and D) of a representative 
CD2-Lmo2-driven T-ALL cell line (03007) transfected with mCherry-expressing empty or 
WT cMYC vector and treated with CAL-130 (72 hours), CompE (27, 96 and 120 hours) 
or DMSO control. Data represent mean ± SEM (***, P < 0.0001; n = 3, t test). cMYC 
protein expression in the same cells treated with CAL-130 (E) or CompE (F) for 24 and 
48 hours, respectively. G, Flow cytometric analysis of disease status in two representative 
(n = 5) Gt(ROSA)26Sortm13(CAG-MYC, -CD2*)Rsky/J; Lck-cre/Pten(fl/fl) mice immediately before 
and 7 days after initiating treatment with dual PI3Kγ/δ inhibitor 
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CAL-130 (10 mg/kg every 8h) for 7 days. Tumor drug response was determined by 
assessing for changes in circulating blasts (Thy1.2+/Ki67+) and propidium iodide (PI)-
staining. 
Figure 5. Blockade of PI3Kγ/δ activity reverses the oncogenic signature of Lmo2-driven 
T-ALL. A, Venn diagram comparing the number and overlap of genes altered by PI3Kγ/δ 
blockade (red circle) or GSI (green circle) using FDR < 0.0005 as cut off. Gene 
expression profiling was performed on triplicate samples of the CD2-Lmo2 T-ALL cell 
line (03007) treated with either CAL-130 (2.5µM, 10 hours) or CompE (1µM, 48 hours) 
as compared to DMSO control. B, Heat map representation of the top 100 differentially 
expressed genes (FDR < 0.00001) between DMSO and CAL-130 or CompE treated 
tumor cells. The scale bar shows color-coded differential expression, with red and blue 
indicating higher and lower levels of expression, respectively. Red arrows denote cMYC-
regulated genes. C, Enrichment of top 100 activated and repressed genes from Lmo2-
driven T-ALL disease signature (T-ALL versus WT mouse thymocytes) on the CAL-130 
(top) and CompE (bottom) activity gene signature. Repressed genes are shown in blue, 
and over-expressed genes are shown in red. D, Comparison of GSI treatment signature 
for tumor cells (top 200 up and down regulated genes) on the consensus GSI 
perturbational signature obtained from the expression profiles (GSE5827) of seven 
human T-ALL cell lines treated with DMSO or CompE. E, Enrichment of top 40 
activated and repressed T-ALL master regulator TFs (as inferred by ViPER based on the 
Lmo2-driven T-ALL versus WT murine thymocyte signature) on the CAL-130 (top) and 
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CompE (bottom) activity signature, respectively. F, Enrichment of cMYC-regulated 
genes on the sorted CAL-130 (top) and CompE (bottom) treatment gene signature.  
Figure 6. PI3Kδ/γ and NOTCH1 regulate metabolic pathways that contribute to the 
oncogenic programming of Lmo2-driven T-ALL. A, Functional annotation of top 297 
genes down regulated (P < 0.00001) in a CAL-130 (2.5 µM, 10 h) treated CD2-Lmo2 T-
ALL cell line (03007) using DAVID. Pathways with Benjamini Hochberg corrected P < 
0.05 are shown. B, Heat map of metabolism-related gene expression profiles after 
CAL-130 or vehicle (DMSO) treatment (in triplicate). Colored bar denotes pathways 
annotated in A, and red and blue indicate high and low levels of gene expression, 
respectively. C, Summary of GSEA performed on the ranked genes according to the 
ratios of transcripts from DMSO, CAL-130 (2.5 µM, 10 h) or CompE (1µM, 48 h) treated 
cells. Six metabolic gene sets with P < 0.01 and a false discovery rate (FDR) of <0.05 
(represents threshold) were considered significant. D, Inhibition of glucose uptake by 
PI3Kγ/δ blockade or NOTCH1 inhibition. Histograms (upper) and mean fluorescence 
intensity (MFI, lower) of 2-NBDG incorporation into tumor cells treated with DMSO, 
CAL-130 (2.5 µM, 14 h) or CompE (1µM, 72 h). Apigenin (100µM, 30 min treatment), 
an inhibitor of Glut1 expression, was used as a positive control. Data represent mean ± 
SEM (**, P < 0.01, ***, P < 0.001 relative to DMSO; n = 3, t test). 
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Figure 7. PI3Kδ/γ regulate distinct bioenergetic pathways that contribute to the 
oncogenic programming of Lmo2-driven T-ALL. A, Summary of mitochondrial GSEA 
analysis performed on the ranked genes according to the ratios of transcripts from 
DMSO, CAL-130 (2.5 µM, 10 h) or CompE (1µM, 48 h) treated cells. Gene sets with a P 
< 0.01 and a false discovery rate (FDR) of < 0.05 (represents threshold) were considered 
significant. B and C, Oxygen consumption rates (OCR) in the same cell line treated with 
DMSO vs. CAL-130 (2.5µM) for 12 hours (B) or DMSO vs. CompE (1µM) for 48 hours 
(C) under basal conditions and in response to the indicated mitochondrial inhibitors. 
Changes after oligomycin and FCCP application are indicative for respiration linked to 
ATP synthesis and the maximal respiratory capacity, respectively. D and E, ATP 
production and spare respiratory capacity in CAL-130 (D) or CompE (E) treated tumor 
cells. Data represent mean ± SEM (***, P < 0.0001, n = 3, t test). F, Respiration of 
mitochondria isolated from a CD2-Lmo2 T-ALL cell line (03007) following exposure to 
CAL-130 (2.5 µM, 12 hours) or DMSO and supported with two different substrates: 
complex-I dependent glutamate-malate (upper panel) or complex-IV linked substrate, 
TMPD-ascorbate (lower panel). Red and black tracings denote drug and DMSO treated 
cells, respectively. The points of initiation of resting, phosphorylating and uncoupled 
respirations are indicated (arrows). The values of the phosphorylating respiration rates 
(PRR) are provided. Schematic substrate-dependent changes in electron supply for 
mitochondrial respiratory chain is presented above each tracing. Insert shows western 
blot analysis for the mitochondria expressed SHMT2 protein in treated tumor cells. 
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